At The Harry Glorikian Show, I, Harry Glorikian, am your host. In short, I have talks with leaders in the healthcare & life sciences industry about the ongoing data-driven transformation of their industry.
From new ways to diagnose & treat patients, bring down costs & creating new value, all the way to AI algorithms that increase efficiency & accuracy, better data is revolutionizing healthcare.
I turn to doctors, hospital administrators, IT directors, entrepreneurs, & others for help mapping out the changes & their impact on everyone from patients to researchers.
Welcome to the show!
All content for The Harry Glorikian Show is the property of Harry Glorikian and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
At The Harry Glorikian Show, I, Harry Glorikian, am your host. In short, I have talks with leaders in the healthcare & life sciences industry about the ongoing data-driven transformation of their industry.
From new ways to diagnose & treat patients, bring down costs & creating new value, all the way to AI algorithms that increase efficiency & accuracy, better data is revolutionizing healthcare.
I turn to doctors, hospital administrators, IT directors, entrepreneurs, & others for help mapping out the changes & their impact on everyone from patients to researchers.
Welcome to the show!
If you look back at all the health-tech and drug development companies Harry has hosted on the show, an interesting pattern starts to emerge: a very large number of those companies have gone on to enormous growth and success in their markets. It could be that being on the podcast is like a catapult to success—or it could be that we're pretty good at finding companies that are already on a promising trajectory. Either way, there's no better example than Concert AI. The company’s CEO, Jeff Elton, first spoke with Harry back in July of 2021. At that time, the company was already one of the leaders in gathering and analyzing broad collections of data about cancer patients involved in clinical trials for new treatments. Its specialty was, and is, going beyond the very specific endpoints measured in clinical trials and looking to electronic medical records, genome sequencing data, insurance claims data, and other sources in order to build a more comprehensive picture of cancer patients and their journeys through the healthcare system. That kind of data can be very useful to companies trying to track the performance of their drugs after they’ve reached the market, and to researchers planning new clinical trials. And since that first conversation, the company has grown by leaps and bounds. It’s taken over management of more data sources, including the massive CancerLinq database formerly maintained by the American Society of Clinical Oncology. It’s struck up partnerships with some of the leading technology startups, research centers, and drug companies working to beat cancer. And it’s leaning hard into the new wave of deep-learning AI tools and their potential to help find patterns in vast amounts of data about patients. It’s probably safe to say that ConcertAI has gathered up more data about cancer patients than any other company on the planet. And investors have been rushing to pour money into the company, on the conviction that data is going to be the key to getting more and better cancer drugs to market. That’s certainly Jeff Elton's conviction too, as you’ll hear in today's interview.
The Harry Glorikian Show
At The Harry Glorikian Show, I, Harry Glorikian, am your host. In short, I have talks with leaders in the healthcare & life sciences industry about the ongoing data-driven transformation of their industry.
From new ways to diagnose & treat patients, bring down costs & creating new value, all the way to AI algorithms that increase efficiency & accuracy, better data is revolutionizing healthcare.
I turn to doctors, hospital administrators, IT directors, entrepreneurs, & others for help mapping out the changes & their impact on everyone from patients to researchers.
Welcome to the show!
